Skip to main content
. Author manuscript; available in PMC: 2024 Jun 1.
Published in final edited form as: Am Heart J. 2023 Mar 7;260:124–140. doi: 10.1016/j.ahj.2023.02.015

Figure 5.

Figure 5

Subgroups of apixaban vs rivaroxaban users with respect to the primary composite endpoint. The subgroups are the terminal nodes of the optimal causal forest model. The green subgroups favor the use of apixaban. All the values were estimated based on the matched sample of apixaban and rivaroxaban users. ATE, average treatment effect; ERPO, events rate per 1,000.